See more : cbdMD, Inc. (YCBD-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Sangamo Therapeutics, Inc. (SGMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sangamo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aker Solutions ASA (AKSO.OL) Income Statement Analysis – Financial Results
- Royal Boskalis Westminster N.V. (BOKA.AS) Income Statement Analysis – Financial Results
- Humatech, Inc. (HUMT) Income Statement Analysis – Financial Results
- Summer Energy Holdings, Inc. (SUME) Income Statement Analysis – Financial Results
- Westpac Banking Corporation (WBC.NZ) Income Statement Analysis – Financial Results
Sangamo Therapeutics, Inc. (SGMO)
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.23M | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M | 36.57M | 19.39M | 39.54M | 45.87M | 24.13M | 21.66M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 3.43M | 2.20M | 2.04M | 1.15M | 632.00K |
| Cost of Revenue | 221.56M | 12.11M | 9.44M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.13M | 56.74M | 36.98M | 31.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.23M | -700.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -45.33M | 99.19M | 101.26M | -62.46M | -43.49M | -30.41M | -29.16M | -46.23M | -27.59M | -10.87M | -12.85M | -10.05M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 8.67M | 2.90M | 2.04M | 1.15M | 632.00K |
| Gross Profit Ratio | -25.72% | 89.12% | 91.47% | -52.84% | -42.46% | -36.01% | -79.75% | -238.43% | -69.78% | -23.71% | -53.23% | -46.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 252.40% | 131.82% | 100.00% | 100.00% | 100.00% |
| Research & Development | 234.06M | 249.90M | 230.82M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.20M | 56.74M | 36.98M | 31.71M | 32.10M | 33.15M | 28.98M | 31.23M | 25.56M | 21.53M | 11.42M | 11.05M | 10.19M | 13.36M | 15.51M | 11.35M | 4.30M | 4.26M | 1.70M | 628.00K |
| General & Administrative | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.26M | 3.59M | 4.16M | 4.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 663.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.92M | 3.59M | 4.16M | 4.75M | 4.57M | 1.80M | 1.24M | 797.00K | 322.00K |
| Other Expenses | 155.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 14.04M | 0.00 | 0.00 | 10.33M | 8.31M | 7.09M | 4.81M | 4.92M | 4.16M | 22.17M | 13.06M | 9.80M | 2.50M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 21.15M | 6.80M | 5.50M | 2.50M | 950.00K |
| Cost & Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 15.92M | 6.10M | 5.50M | 2.50M | 950.00K |
| Interest Income | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.00K | 81.00K | 0.00 | 2.23M | 3.22M | 2.41M | 850.00K | 620.00K | 752.00K | 1.37M | 3.19M | 3.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.19M | 12.11M | 9.44M | 5.68M | 3.93M | 2.36M | 1.50M | 997.00K | 988.00K | 549.00K | 569.00K | 660.00K | 646.00K | 676.00K | 572.00K | 523.00K | -1.87M | -686.00K | 488.00K | 1.48M | 2.17M | 2.51M | 4.31M | 5.23M | 700.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.43M | -189.17M | -173.90M | -123.87M | -101.25M | -74.79M | -54.86M | -70.68M | -45.80M | -26.23M | -26.08M | -21.54M | -35.10M | -24.18M | -18.83M | -24.85M | -24.77M | -20.73M | -13.26M | -13.38M | -9.60M | -27.89M | -11.07M | -7.25M | -3.20M | -3.46M | -1.35M | -318.00K |
| EBITDA Ratio | -49.61% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -57.38% | -110.16% | -102.51% | -347.14% | -119.85% | -86.08% | -146.39% | -273.08% | -268.65% | -505.80% | -1,017.64% | -372.82% | -247.18% | 40.80% | -211.21% | -145.45% | -169.68% | -116.75% | -50.32% |
| Operating Income | -274.01M | -201.28M | -183.34M | -129.55M | -105.18M | -77.15M | -56.36M | -72.56M | -46.86M | -26.78M | -26.71M | -22.20M | -35.82M | -24.94M | -19.40M | -25.38M | -24.77M | -20.73M | -13.75M | -14.65M | -11.77M | -31.57M | -28.44M | -12.48M | -3.90M | -3.46M | -1.35M | -318.00K |
| Operating Income Ratio | -155.48% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -58.38% | -110.66% | -102.51% | -347.14% | -119.85% | -87.45% | -156.77% | -272.27% | -262.89% | -553.46% | -1,114.07% | -456.34% | -726.80% | -582.21% | -363.62% | -177.27% | -169.68% | -116.75% | -50.32% |
| Total Other Income/Expenses | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 1.79M | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 71.00K | 81.00K | 815.00K | 1.07M | 3.29M | 2.87M | 455.00K | 832.00K | 1.34M | 1.80M | 3.19M | 0.00 | 0.00 | 3.46M | 1.35M | 318.00K |
| Income Before Tax | -262.90M | -191.85M | -177.99M | -120.78M | -95.42M | -68.89M | -54.57M | -71.67M | -46.43M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -149.18% | -172.37% | -160.79% | -102.19% | -93.16% | -81.57% | -149.23% | -369.65% | -117.42% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.07M | 429.00K | 306.00K | 345.00K | -19.60M | 8.26M | -1.50M | -14.00K | -5.72M | -683.00K | -591.00K | -660.00K | -646.00K | -676.00K | -815.00K | -1.07M | -1.42M | -2.18M | -455.00K | -832.00K | -1.34M | -1.43M | 9.87M | -3.42M | -100.00K | 3.29M | 1.40M | 308.00K |
| Net Income | -257.83M | -192.28M | -178.30M | -121.12M | -75.82M | -68.33M | -54.57M | -71.66M | -40.70M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | -9.07M | -3.80M | -3.29M | -1.40M | -308.00K |
| Net Income Ratio | -146.30% | -172.76% | -161.06% | -102.48% | -74.02% | -80.91% | -149.23% | -369.58% | -102.94% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | -264.08% | -172.73% | -161.19% | -121.53% | -48.73% |
| EPS | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| EPS Diluted | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| Weighted Avg Shares Out | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
| Weighted Avg Shares Out (Dil) | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , April 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sangamo Therapeutics, Inc....
Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength?
Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF CAR-TREG CELL THERAPY TX200 IN KIDNEY TRANSPLANTATION
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product...
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cowen 42nd Annual Health Care Conference Date: Monday, March 7th at 12:50 p.m. Eastern Time Barclays Global...
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cowen 42nd Annual Health Care Conference Date: Monday, March 7th at 12:50 p.m. Eastern Time Barclays Global...
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to advance the development of genomic medicines for patients across multiple...
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to advance the development of genomic medicines for patients across multiple...
Source: https://incomestatements.info
Category: Stock Reports